^
Association details:
| Biomarker: | MUC16 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
5426 / 9 - Multi-omic characterization and predictive features of advanced ovarian cancer patients in a large phase III cohort Add to My Itinerary
Published date:
03/15/2023
Excerpt:
800+ advanced ovarian cancer patients enrolled in the phase III trial of the PARP-1 inhibitor Veliparib (VELIA)….Pairwise analysis of individual features with clinical outcomes shows that increased tumor-mutation burden (TMB)...were each significantly associated with longer PFS and less progressive disease (PD). Similarly, homologous recombination deficiency (HRD) and BRCA alteration were associated with better clinical outcomes, while high CA-125 was associated with worse outcomes.
